Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
June 30, 2023 09:06 AM EDTUpdated 03:25 PM
Deals
Pharma

All eyes on Brent Saun­ders: Bausch + Lomb deal­mak­er to buy Xi­idra from No­var­tis in $1.75B deal

Kyle LaHucik

Senior Reporter

Brent Saun­ders is mak­ing deals yet again.

In his re­turn to the helm of Bausch + Lomb, Saun­ders will broad­en the eye-care com­pa­ny’s port­fo­lio with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times